Acquisition Announced
UCB acquisition of Candid Therapeutics
US$2.2bn consideration
Announced 4 May 2026
Advisers
Candid Therapeutics
Target
UCB
Acquirer
Not disclosed
Other advisers
- Financial adviser
- Target
- Candid Therapeutics
- Acquirer
- UCB
- Target based in
- United States
- Buyer based in
- Belgium
- Sector
- Biotech
- Tags
- Biotech, Drug Development
In the league tables
Similar deals
- argenx SE acquisition of Forte Biosciences Jul 2026 · US$2.2bn · Biotech
- Eli Lilly and Company acquisition of Ajax Therapeutics Apr 2026 · US$2.3bn · Biotech
- GSK acquisition of RAPT Therapeutics Jan 2026 · US$2.2bn · Biotech
- Novartis acquisition of Pikavation Mar 2026 · US$2bn · Biotech
- Gilead acquisition of Ouro Medicines Mar 2026 · US$1.7bn · Biotech
